ANI launches generic Questran
ANI Pharmaceuticals has introduced its generic Questran (cholestyramine for oral suspension). The drug is indicated as an adjunct to diet and exercise for reduction of high cholesterol in patients with primary hypercholesterolemia who do not respond adequately to diet.
Baudette, Minn.-based ANI’s generic Questran will be available in cans, 4g/dose. The product’s annual market size is roughly $22 million, according to IQVIA data. The launch is part of ANI’s ongoing efforts to re-commercialize discontinued generics that the company recently acquired.
“This launch is the 10th product that ANI has successfully completed a manufacturing site transfer and re-commercialized,” ANI president and CEO Arthur Przybyl said. “These product launches are from previously discontinued ANDA's that ANI has acquired over the last several years. We continue to commit product development resources in order to launch additional discontinued ANDA's that we believe can provide us with meaningful cash flow once re-commercialized.”
Baudette, Minn.-based ANI’s generic Questran will be available in cans, 4g/dose. The product’s annual market size is roughly $22 million, according to IQVIA data. The launch is part of ANI’s ongoing efforts to re-commercialize discontinued generics that the company recently acquired.
“This launch is the 10th product that ANI has successfully completed a manufacturing site transfer and re-commercialized,” ANI president and CEO Arthur Przybyl said. “These product launches are from previously discontinued ANDA's that ANI has acquired over the last several years. We continue to commit product development resources in order to launch additional discontinued ANDA's that we believe can provide us with meaningful cash flow once re-commercialized.”